Chau Cindy H, Strope Jonathan D, Figg William D
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Pharmacotherapy. 2020 Aug;40(8):857-868. doi: 10.1002/phar.2439.
Given the global nature of the coronavirus disease 2019 (COVID-19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID-19 diagnostics on the horizon. Antibody response against SARS-CoV-2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.
鉴于2019冠状病毒病(COVID-19)大流行的全球性,疾病检测和扩大检测能力的需求仍然是关键优先事项。本综述讨论了目前用于检测新型冠状病毒或正在开发中的检测能力和方法的技术进展。我们描述了目前用于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)检测的临床诊断方法和技术,包括分子和血清学检测方法,并阐述了它们的优点和局限性。用于分子诊断的核酸扩增技术仍然是病毒检测的金标准。我们重点介绍了即将用于开发新型COVID-19诊断方法的替代分子检测技术。对SARS-CoV-2的抗体反应仍知之甚少,血清学检测的适当验证对于证明其准确性和临床实用性至关重要。为了控制疫情,我们必须通过改进临床诊断和检测技术以及这些工具的可及性,加快快速和广泛检测的开发。